omeprazole / Generic mfg. - LARVOL DELTA

Intensive Adverse Drug Reaction Monitoring Program Improves Detection of Phenytoin-Induced Adverse Drug Reactions. (PubMed, Patient Prefer Adherence) - "To compare the outcomes of routine versus intensive adverse drug reaction (ADR) monitoring programs among adult in-patients initially treated with phenytoin, and to identify risk factors associated with severe cutaneous adverse reactions (SCARs). Comorbidities, concomitant omeprazole use, and older age were associated with SCARs. Intensive monitoring programs may enhance patient engagement and improve medication safety by enabling timely recognition and management of adverse reactions."

Adverse drug reaction • Journal

Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan. (PubMed, Drug Healthc Patient Saf) - "Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

REAL-WORLD RISK OF DRUG-INDUCED TUBULOINTERSTITIAL NEPHRITIS (ISN-WCN 2026) - "As shown in Figure 1a, 11 such drugs were identified: omeprazole, ibuprofen, pantoprazole, ciprofloxacin, pembrolizumab, nivolumab, vancomycin, carboplatin, pemetrexed, tacrolimus, and esomeprazole.The relationship between TIN and these suspected drugs is illustrated in the volcano plot (Figure 1a). Individuals aged over 60 years, male, or those who have taken 9 specific drugs including omeprazole are at a higher risk of developing DITIN. The findings of this study can provide important information for the early identification of drug-related acute interstitial nephritis and lay a foundation for future research on the pathogenesis of DITIN."

Clinical • Real-world • Real-world evidence • Immunology • Infectious Disease • Nephrology • Respiratory Diseases • Tuberculosis

Asiatic Acid Ameliorates Indomethacin-Induced Gastric Ulcers in Rats Through Enhancement of TGF-β1. (PubMed, J Biochem Mol Toxicol) - "Group 6: administered oral omeprazole (30 mg/kg) prior to indomethacin. Asiatic acid in orange oil shows significant protective effects against indomethacin-induced gastric ulcers in rats. It improves both macroscopic and microscopic gastric mucosal features while restoring TGF-β1 levels, promoting tissue repair and healing."

Journal • Preclinical • Gastroenterology • Inflammation • Peptic Ulcer • TGFB1

Association between omeprazole and memory impairment: Insights from NHANES data analysis and network pharmacology studies. (PubMed, J Alzheimers Dis) - "The top 10 potential binding targets of omeprazole-UBA52, RPL23, RPS18, RPL4, RPL15, RPL11, RPS6, EGFR, RPL13, and RPS20-exhibited strong binding affinities. The enrichment analysis implies a role for omeprazole in causing memory issues, possibly by affecting processes like carboxylic acid metabolism and membrane transportation.ConclusionsMounting research from both large-scale population studies and drug safety surveillance reports paints a clear picture: regular omeprazole consumption appears to hike the chances of experiencing cognitive hiccups related to memory function."

Journal • Alzheimer's Disease • CNS Disorders • EGFR • RPL11 • RPL13 • RPL23 • RPS6 • UBA52

Prevalence of Missed Medication Doses and Outcomes of Hospitalized Patients Living with HIV in Uganda. (PubMed, Drug Healthc Patient Saf) - "Missed doses were common across nearly all medications, with omission rates exceeding 80% for ceftriaxone, paracetamol, metronidazole, omeprazole, metoclopramide, and levofloxacin, and approaching 100% for furosemide, co-amoxiclav, ondansetron, enoxaparin, albumin, and artesunate. Missed parenteral medication doses are highly prevalent among hospitalized PLHIV in Uganda. Strengthening medication administration and documentation systems is urgently needed to improve patient safety and outcomes."

Journal • Human Immunodeficiency Virus • Infectious Disease

FASN: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Apr 2030 ➔ Mar 2028

Trial completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (clinicaltrials.gov) - P3 | N=121 | Completed | Sponsor: Beni-Suef University

New P3 trial • Infectious Disease

Pharmacokinetics, Safety, and Tolerability of GS-1427, an Oral Prodrug of a Potent and Selective α4β7 Integrin Inhibitor, in Healthy Participants. (PubMed, J Clin Pharmacol) - "The bioavailability of tablet versus capsule formulations and the effect of food and an acid-reducing agent (omeprazole) on exposure were also assessed. All AEs were grade 1 in severity and no serious AEs or deaths were reported. The pharmacokinetics, safety, and tolerability results from this study support further evaluation of GS-1427 in a phase 2 trial in patients with UC."

Clinical • First-in-human • Journal • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

OPEN-IT: OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (clinicaltrials.gov) - P4 | N=122 | Recruiting | Sponsor: Stephen Firkins | Trial completion date: Dec 2025 ➔ Mar 2027 | Trial primary completion date: Dec 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Peptic Ulcer

Proton-pump inhibitor Omeprazole did not affect the plasma pharmacokinetics of Bemnifosbuvir and Ruzasvir fixed-dose combination in healthy participants (EASL 2026) - No abstract available

Clinical • PK/PD data • Hepatitis C • Hepatology • Infectious Disease

Drug-Induced Thrombocytopenia from Proton Pump Inhibitors and H₂ Blockers: A Systematic Review and Comparative Analysis of Published Case Reports (THSNA 2026) - "Representative PPI reports (pantoprazole, lansoprazole, omeprazole/esomeprazole) and classical H₂RA reports (cimetidine, ranitidine, famotidine) were abstracted for onset (days), recovery (days), bleeding and ICU status. Case-level evidence indicates both PPIs and H₂RAs can cause abrupt, reversible thrombocytopenia with onset within days and recovery within 1–2 weeks; PPI reports show a trend toward earlier onset and higher bleeding documentation. Findings are limited by reporting bias and small numbers; prospective pharmacovigilance and mechanistic testing are needed to confirm class-specific risks. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Case report • Clinical • Review • Hematological Disorders • Thrombocytopenia

Which quadruple therapy should be prescribed as first-line treatment for Helicobacter pylori infection? Results of a prospective study comparing concomitant and bismuth therapy. (PubMed, Arab J Gastroenterol) - "Both concomitant and bismuth quadruple therapies are effective, safe, and well-tolerated first-line treatments for H. pylori eradication, achieving > 75 % eradication rates. The choice of regimen may depend on local resistance patterns, cost, and patient-specific factors. Further multicenter studies with resistance profiling are warranted."

Journal • Extranodal Marginal Zone Lymphoma • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Oncology • Peptic Ulcer • Solid Tumor

Lightning strikes thrice: a case report of triple positive ANCA associated vasculitis (UKKW 2026) - "She had taken short courses of traditional Chinese medicine herbal remedies, ibuprofen, naproxen, and omeprazole for treatment of her joint stiffness...She was treated for Anca-Associated Vasculitis (AAV) with rituximab and cyclophosphamide: the prednisolone was later converted to avacopan. Hepatitis B core antibody was positive so she was also started on lamivudine prophylaxis...Few cases have been described where other autoantibodies are also positive. Patient’s consent: the patient has given verbal documented consent and written consent for publication."

Case report • Clinical • ANCA Vasculitis • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis

Remission of PR3 associated vasculitis in a 16 year old patient with avacopan (UKKW 2026) - "He was initially treated for a lower respiratory tract infection with ceftriaxone and clarithromycin...He was treated for ANCA associated vasculitis with three pulses of 500mg methylprednisolone daily, followed by a weaning course of prednisolone, and 2 doses of rituximab alongside co-trimoxazole, omeprazole, and vitamin D prophylaxis: cyclophosphamide was avoided due to concerns regarding fertility...Repeat imaging six months after the first CT showed that the previously demonstrated multiple bilateral pulmonary nodules had completely resolved with residual lung cysts (Figure 1). This case provides an example of the potential role of avacopan in treatment of ANCA associated vasculitis in adolescents, where avoiding prolonged glucocorticoid use and preservation of fertility is key to reducing treatment related morbidity and supporting long term psychosocial and wellbeing."

Clinical • ANCA Vasculitis • Cough • Hematological Disorders • Infectious Disease • Musculoskeletal Pain • Respiratory Diseases • Vasculitis

Study of Treatment with Intensified Omeprazole to Prevent High-Output Stoma-A Protocol for a Randomized, Parallel-Group, Open-Label, Superiority Trial in Adults Undergoing Ileostomy (STOP-HOS-1). (PubMed, J Clin Med) - "STOP-HOS-1 will provide the first randomized evidence on whether intensified postoperative PPI therapy reduces early ileostomy output and HOS-related morbidity, informing future standards of care."

Head-to-Head • Journal • Acute Kidney Injury • Cardiovascular • Heart Failure • Nephrology • Renal Disease

EARLY POST-TRANSPLANT EOSINOPHILIC GASTROENTERITIS IN TWO ALLOGENIC HSCT RECIPIENTS (EBMT 2026) - "The patient's symptoms resolved along with the peripheral eosinophilia in less than 2 weeks with the avoidance of dairy products and the administration of omeprazole (20 mg/day) without corticosteroid therapy... EGE is a rare GI complication after allo-HSCT that may mimic other transplant complications such as infectious colitis and GvHD. Systematic endoscopic and histologic evaluation was critical to establishing the diagnosis and avoiding unnecessary immunosuppression. Both patients showed excellent response with a lactose-free diet, behaving as if they had developed lactose intolerance."

Post-transplantation • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Eosinophilia • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Inflammation • Metabolic Disorders • Transplantation • TP53

A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: University of Michigan Rogel Cancer Center | Recruiting ➔ Completed | Trial completion date: Sep 2026 ➔ Feb 2026

Biomarker • Trial completion • Trial completion date • Colorectal Cancer • Oncology • Solid Tumor

Hypersensitivity reactions with proton pump inhibitors: five years of clinical experience. (PubMed, Allergol Immunopathol (Madr)) - "Skin testing is a valuable tool in predicting hypersensitivity reactions associated with PPIs. Although rare, hypersensitivity reactions may occur in patients with negative skin tests."

Journal • Retrospective data • Allergy • Immunology

Community-based management of gastrointestinal symptoms at end-of-life in scleroderma using subcutaneous medication: a case report. (PubMed, Ann Palliat Med) - "This case illustrates the safe and effective use of subcutaneous omeprazole for managing upper gastrointestinal symptoms at the end of life in a community setting. It supports the role of flexible prescribing and individualised care to respect patient preferences. Due the unpredictable physiology of people at the end-of-life and the challenges in palliative care research, case reports and expert opinion remain vital evidence for clinical practice."

Journal • Gastroenterology • Gastroesophageal Reflux Disease • Immunology • Palliative care • Rheumatology • Scleroderma • Systemic Sclerosis

Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials. (PubMed, EClinicalMedicine) - "At 8 weeks, zastaprazan 20 mg, vonoprazan 20 mg, and esomeprazole 40 mg demonstrated moderate-certainty superiority over rabeprazole 20 mg and omeprazole 20 mg with RDs ranging from 0.05 to 0.11, while only vonoprazan 20 mg demonstrated moderate-certainty benefit versus lansoprazole 30 mg (RD: 0.04)...Vonoprazan 20 mg and rabeprazole-ER 50 mg demonstrated moderate-certainty benefit compared with pantoprazole 40 mg (RDs: 0.12 and 0.09, respectively).At 24 weeks, vonoprazan 10 mg and 20 mg showed moderate-to-high-certainty benefit versus lansoprazole 15 mg (RDs: -0.11 and -0.13, respectively), while in direct comparisons, esomeprazole 20 mg outperformed lansoprazole 15 mg and pantoprazole 20 mg, with approximately 40-50% relative reductions in recurrence...Comparative trials evaluating newer P-CABs against optimized PPI strategies, including twice-daily dosing, are needed to evaluate efficacy and long-term safety, particularly with respect to hypergastrinemia and infection..."

Journal • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease

Developing and Evaluating Stable Microemulsion Systems for Potential Intranasal and Transdermal Application of Omeprazole. (PubMed, AAPS PharmSciTech) - "The in vivo study demonstrated that the relative bioavailabilities of the intranasal and transdermal administration were 332% and 103%, respectively, compared to an oral solution. Overall, the formulated microemulsions were stable and could serve as effective carriers, making them promising delivery systems for omeprazole delivery via transdermal and intranasal routes."

Journal

KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (clinicaltrials.gov) - P=N/A | N=12 | Completed | Sponsor: Helsinki University Central Hospital | Not yet recruiting ➔ Completed

Trial completion • Congestive Heart Failure

Comparative Effectiveness of Omeprazole and Lansoprazole in Gastroesophageal Reflux Disease (GERD): A Review Article. (PubMed, JNMA J Nepal Med Assoc) - "Based on the adverse effects of the drug, Omeprazole has a lower potential risk of causing diarrhea. Omeprazole has the most minimal cost analysis when viewed from the cost aspect and Omeprazole has a faster onset than Lansoprazole."

HEOR • Journal • Review • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

A RARE PRESENTATION IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS –"LIKE IN LOOKS, SO IN THE EYES" (SSWC 2026) - "Her medica- tions were omeprazole only...She received Bevacizumab (an anti-an- giogenic agent; an anti-VEGF-A agent) with which she appa- rently seems to have stabilized temporarily... Eye manifestations, the appropriate guideli- nes for screening and their treatment of SSc remains an unmet need. Literature review by K. Paczwa et al have illustrated the various ocular manifestations of SSc in their review based on case reports or short small studies only. Our patient is a very young lady with stable lcSSc with minimal mRSS score, as well as had infrequent raynauds, nevertheless still developed CRVO with its inherent morbidity of diminished vision."

Fibrosis • Immunology • Inflammation • Retinal Disorders • Retinal Vein Occlusion • Scleroderma • Systemic Sclerosis